SUBSCRIBE
SUBSCRIBE
News   Drug Development

Array BioPharma, Inc. Initiates Phase 1 Clinical Trial for MEK Inhibitor ARRY-300

January 9, 2009 | 
1 min read
BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) has initiated dosing in healthy volunteers in a Phase 1 clinical trial with ARRY-300, a targeted small molecule MEK inhibitor.
Clinical research Phase 1
MORE ON THIS TOPIC
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
 · 
1 min read
 · 
Heather McKenzie